Dinaciclib, a small-molecule inhibitor of CDK 1, 2, 5 and 9, has been shown to downregulate Mcl-1 and has activity in hematologic malignancies, including AML.107 It is currently in several clinical trials for both solid and liquid tumors, including a phase I clinical trial in combination with venetoclax for R/R AML (NCT03484520). Here, MCL1 is linked to hematologic disorder.